Skip to main content
Bavarian Nordic logo

Bavarian Nordic — Investor Relations & Filings

Ticker · BAVA ISIN · DK0015998017 LEI · 2138006JCDVYIN6INP51 CO Manufacturing
Open in API
Filings indexed 2,303 across all filing types
Latest filing 2023-06-27 Regulatory Filings
Country DK Denmark
Listing CO BAVA

About Bavarian Nordic

https://www.bavarian-nordic.com/

Bavarian Nordic is a fully integrated biotechnology company specializing in the research, development, manufacturing, and commercialization of life-saving vaccines. The company's portfolio targets infectious diseases, including vaccines for Mpox, rabies, and typhoid. It is a leading global provider of travel vaccines and serves as a key partner for governments and international organizations in addressing public health preparedness needs.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings Classification · 99% confidence The document is a press release from Bavarian Nordic announcing the top-line results from a Phase 3 trial for its COVID-19 booster vaccine candidate (ABNCoV2). It details the trial's primary endpoint achievement (non-inferiority) and mentions that secondary endpoints and the path to regulatory approval depend on future results expected in Q3 2023. This structure—an immediate announcement of key trial data and business updates—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a specific announcement of results rather than a comprehensive periodic report (like 10-K or IR), and it is not a transcript (CT) or a formal presentation (IP), the most fitting category for a timely, results-focused press release is 'Earnings Release' (ER), as these often accompany or precede formal earnings reports, or 'Regulatory Filings' (RNS) if it's purely informational. Given the focus on clinical trial results and business progress, ER is often used for such material updates, but RNS is the general catch-all for non-standard regulatory news. However, since this is a major operational update announcing trial success, it functions similarly to an earnings highlight. Given the options, and recognizing this is a material announcement of operational/clinical progress, ER is a strong candidate, but RNS covers general regulatory announcements well. Since the document is a formal 'Selskabsmeddelelse' (Company Announcement) and details clinical trial outcomes which are material, it fits best under the general regulatory announcement category (RNS) or potentially ER if it were tied to a specific reporting period's earnings cycle. Since it is a standalone announcement of trial results, RNS (Regulatory Filings) is the safest general classification for material, non-standard reports, although ER is plausible if this was released near an earnings date. I will classify it as RNS as it is a general regulatory announcement detailing clinical progress, which is not explicitly covered by ER (which usually focuses on financial figures). The document length (5979 chars) is substantial enough that it is not just a simple RPA.
2023-06-27 Danish
Earnings Release 2023
Earnings Release Classification · 100% confidence The document is titled "Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate" and details the results of a clinical trial, including meeting the primary objective and outlining future reporting timelines (Q3 2023). This content strongly suggests an announcement of significant operational/clinical progress, which is typical for an Earnings Release (ER) or a general announcement. However, the core subject is the reporting of clinical trial results, which is a key component of investor updates. Since it is a headline announcement of results rather than a comprehensive financial report (10-K or IR), ER is a strong candidate. It is not a transcript (CT), a formal audit report (AR), or a management discussion (MDA). Given the focus on clinical trial results and the immediate release of topline data, this fits best as an Earnings Release (ER) or potentially an Investor Presentation (IP) if it were a slide deck, but as a press release announcing results, ER is the most appropriate fit among the options provided for immediate financial/operational news. Q2 2023
2023-06-27 English
Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate
Regulatory Filings Classification · 95% confidence The document is a corporate announcement (Selskabsmeddelelse) from Bavarian Nordic regarding the topline results of a Phase 3 clinical trial for their COVID-19 vaccine candidate. It details the trial's primary goals, outcomes, and future regulatory steps. As it is an initial announcement of clinical trial results rather than a full financial report or a regulatory filing for a specific event like a dividend or board change, it falls under the category of a general regulatory announcement or corporate news release.
2023-06-27 Danish
Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate
Regulatory Filings Classification · 95% confidence The document is a company announcement from Bavarian Nordic regarding the topline results of a Phase 3 clinical trial for a COVID-19 vaccine candidate. It details the study objectives, methodology, and results, and provides forward-looking statements. It does not fit into specific financial reporting categories like 10-K or IR, nor is it a simple report publication announcement. As it is a general regulatory/corporate announcement regarding business operations and clinical trial progress, it falls under the RNS (Regulatory Filings) category.
2023-06-27 English
Regulatory Filings 2023
Regulatory Filings Classification · 98% confidence The document is a short announcement dated June 23, 2023, detailing a contract award for supplying smallpox vaccines to the EU strategic reserve (rescEU). It contains key highlights, quotes from the CEO, and boilerplate information about the company and forward-looking statements. It is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a formal proxy/remuneration document. Since it announces a significant business event (a contract award) that impacts operations and future revenue, it fits best under a general business update or regulatory filing category. Given the options, it is a specific business announcement that doesn't fit the highly specialized categories like DIV, DIRS, or NAV. It is most appropriately classified as a general Regulatory Filing (RNS) as it is a 'Company Announcement' regarding a material contract, or potentially a Capital/Financing Update (CAP) if the contract value was the primary focus, but RNS serves as the best general catch-all for material, non-standard announcements.
2023-06-23 English
Regulatory Filings 2023
Regulatory Filings Classification · 98% confidence The document is titled "*Selskabsmeddelelse*" (Company Announcement) and details a specific business event: Bavarian Nordic securing a contract to supply smallpox vaccines to the EU's rescEU strategic reserve. This is a material, non-periodic business update concerning a significant contract and future delivery expectations. It is not a full annual report (10-K), an interim report (IR), an earnings release (ER), or a transcript (CT). Since it announces a specific business development, contract, or material event that doesn't fit the other specific categories (like DIRS, DIV, CAP), it falls best under the general regulatory announcement category, which is RNS (Regulatory Filings), as it is a formal announcement to the market about a significant event. Given the short length (4064 chars) and the nature of being a formal announcement of a contract, RNS is the most appropriate general classification if a more specific 'Contract Award' code were not available. However, since it details a significant business transaction/update, and is not a proxy statement, dividend notice, or capital change, RNS serves as the best fit among the provided options for a general, material regulatory announcement.
2023-06-23 Danish

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.